A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.

Criteria

Inclusion Criteria:

• Signed informed consent

• Previous participation in Study ACD2600g

• For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion Criteria:

• Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab